Business Context and Reporting Period
This Form 8-K Current Report was filed by Aardvark Therapeutics, Inc. on February 12, 2026, covering events occurring on February 9, 2026. The filing details significant executive leadership changes and the establishment of a new wholly-owned subsidiary, Ardia Therapeutics, Inc., to support a dermatology pipeline focused on the lead asset DIA-615.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on corporate governance and personnel changes.
Material Changes
- Departure of Chief Operating Officer: Bryan Jones, Ph.D., ceased serving as Chief Operating Officer effective February 9, 2026, to become the Chief Executive Officer of the new subsidiary, Ardia Therapeutics, Inc.
- Appointment of Chief Operating Officer: Nelson Sun, the current Chief Financial Officer, was appointed as Chief Operating Officer effective February 9, 2026, while retaining his CFO role. There is no material change to his compensation.
- Appointment of Chief Business Officer: Derrick C. Li was appointed as Chief Business Officer (announced February 12, 2026).
- Establishment of Subsidiary: The Company established Ardia Therapeutics, Inc., to develop a dermatology pipeline, specifically targeting inflammatory skin diseases like psoriasis with asset DIA-615.
Compensation Arrangements and Contingencies
Dr. Jones entered into a Letter Agreement regarding his transition:
- Severance Waiver: Dr. Jones waived rights to compensation under the Company's Severance Plan.
- Salary Protection: If Dr. Jones is terminated by Ardia within nine months of the separation date, the Company will pay salary for the remaining period up to the nine-month anniversary, subject to a release.
- Health Insurance: Similar to salary, the Company will cover approximate insurance premium contributions if Dr. Jones is terminated by Ardia within nine months, subject to a release.
- Equity Vesting: Vesting of 17,797 shares subject to stock options was accelerated as of the separation date. An additional 2,542 shares will vest on each one-month anniversary through the three-month anniversary.
- Option Exercise: The post-termination exercise period for existing options will not commence as long as Dr. Jones remains employed by Ardia.
Investor Verification Checklist
- Verify the operational status and funding structure of the new subsidiary, Ardia Therapeutics, Inc.
- Review the full text of the Letter Agreement (Exhibit 10.1) to confirm specific terms regarding Dr. Jones's potential severance and equity vesting.
- Assess the impact of Nelson Sun holding dual roles as CFO and COO on the Company's financial oversight and operational execution.
- Monitor the development timeline and clinical strategy for the dermatology lead asset, DIA-615.